Prostate Cancer Small Non-coding RNA Transcriptome in Arabs

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2017 Dec 23

PMID 29268752

Citations 4

Authors

Jingxuan Shan

Khalid Al-Rumaihi

Karim Chouchane

Issam Al-Bozom

Danny Rabah

Karim Farhat

Lotfi Chouchane

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer (PCa) is a complex disorder resulting from the combined effects of multiple environmental and genetic factors. Small non-coding RNAs (sRNAs), particularly microRNAs (miRNAs), regulate several cellular processes and have an important role in many human malignancies including PCa. We assessed the sRNA profiles associated with PCa in Arabs, a population that has rarely been studied.

Methods: We used next generation sequencing technology to obtain the entire sRNA transcriptome of primary prostate tumor formalin-fixed paraffin-embedded tissues, and their paired non-tumor tissues, collected from Bedouin patients (Qatari and Saudi). The miRNA and the target gene expression were evaluated by real-time quantitative PCR. miRNA KEGG pathway and miRNA target genes were subsequently analyzed by starBase and TargetScan software.

Results: Different expression patterns of several sRNA and miRNA editing were revealed between PCa tumor and their paired non-tumor tissues. Our study identified four miRNAs that are strongly associated with prostate cancer, which have not been reported previously. Differentially expressed miRNAs significantly affect various biological pathways, such as cell cycle, endocytosis, adherence junction and pathways involved in cancer. Prediction of potential targets for the identified miRNAs indicates the overexpression of KRAS, BCL2 and down-regulation of PTEN in PCa tumor tissues.

Conclusion: These miRNAs, newly associated with prostate cancer, may represent not only markers for the increased risk of PCa in Arabs, but may also reflect the clinical and pathological diversity as well as the ethno-specific heterogeneity of prostate cancer.

Citing Articles

Differential Protein-Coding Gene Expression Profile in Patients with Prostate Cancer.

Albarracin-Navas L, Almonte-Becerril M, Guerrero E, Rivadeneira J, Telechea-Fernandez M, Guzman E Biomedicines. 2024; 12(11).

PMID: 39595075 PMC: 11592252. DOI: 10.3390/biomedicines12112509.

Reference Genes for qPCR-Based miRNA Expression Profiling in 14 Human Tissues.

Veryaskina Y, Titov S, Zhimulev I Med Princ Pract. 2022; 31(4):322-332.

PMID: 35354155 PMC: 9485981. DOI: 10.1159/000524283.

MicroRNAs as Guardians of the Prostate: Those Who Stand before Cancer. What Do We Really Know about the Role of microRNAs in Prostate Biology?.

Andl T, Ganapathy K, Bossan A, Chakrabarti R Int J Mol Sci. 2020; 21(13).

PMID: 32645914 PMC: 7370012. DOI: 10.3390/ijms21134796.

Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.

Abdelsalam R, Khalifeh I, Box A, Kalantarian M, Ghosh S, Abou-Ouf H J Cancer Res Clin Oncol. 2020; 146(7):1701-1709.

PMID: 32350606 DOI: 10.1007/s00432-020-03221-x.

References

Yang J, Li J, Shao P, Zhou H, Chen Y, Qu L . starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2010; 39(Database issue):D202-9. PMC: 3013664. DOI: 10.1093/nar/gkq1056. View

Ahmad A, Azim S, Zubair H, Khan M, Singh S, Carter J . Epigenetic basis of cancer health disparities: Looking beyond genetic differences. Biochim Biophys Acta Rev Cancer. 2017; 1868(1):16-28. PMC: 5513784. DOI: 10.1016/j.bbcan.2017.01.001. View

Rawlings-Goss R, Campbell M, Tishkoff S . Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics. 2014; 7:53. PMC: 4159108. DOI: 10.1186/1755-8794-7-53. View

Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K . Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005; 96(2):111-5. PMC: 11158408. DOI: 10.1111/j.1349-7006.2005.00015.x. View

Park J . Promoter hypermethylation as a biomarker in prostate adenocarcinoma. Methods Mol Biol. 2014; 1238:607-25. DOI: 10.1007/978-1-4939-1804-1_32. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

Dong X, Rodriguez C, Guo P, Sun X, Talbot J, Zhou W . SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet. 2008; 17(7):1031-42. PMC: 2923223. DOI: 10.1093/hmg/ddm375. View

10.

Bhardwaj A, Srivastava S, Khan M, Prajapati V, Singh S, Carter J . Racial disparities in prostate cancer: a molecular perspective. Front Biosci (Landmark Ed). 2016; 22(5):772-782. PMC: 5242333. DOI: 10.2741/4515. View

11.

Salim E, Moore M, Al-Lawati J, Al-Sayyad J, Bazawir A, Bener A . Cancer epidemiology and control in the arab world - past, present and future. Asian Pac J Cancer Prev. 2009; 10(1):3-16. View

12.

Croce C . Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10(10):704-14. PMC: 3467096. DOI: 10.1038/nrg2634. View

13.

Chawla G, Sokol N . ADAR mediates differential expression of polycistronic microRNAs. Nucleic Acids Res. 2014; 42(8):5245-55. PMC: 4005697. DOI: 10.1093/nar/gku145. View

14.

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

15.

Kawahara Y, Zinshteyn B, Sethupathy P, Iizasa H, Hatzigeorgiou A, Nishikura K . Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science. 2007; 315(5815):1137-40. PMC: 2953418. DOI: 10.1126/science.1138050. View

16.

Catto J, Alcaraz A, Bjartell A, de Vere White R, Evans C, Fussel S . MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011; 59(5):671-81. DOI: 10.1016/j.eururo.2011.01.044. View

17.

Mihailescu R . Gene expression regulation: lessons from noncoding RNAs. RNA. 2015; 21(4):695-6. PMC: 4371337. DOI: 10.1261/rna.050815.115. View

18.

Ender C, Krek A, Friedlander M, Beitzinger M, Weinmann L, Chen W . A human snoRNA with microRNA-like functions. Mol Cell. 2008; 32(4):519-28. DOI: 10.1016/j.molcel.2008.10.017. View

19.

Godfrey A, Xu Z, Weinberg C, Getts R, Wade P, DeRoo L . Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res. 2013; 15(3):R42. PMC: 3706791. DOI: 10.1186/bcr3428. View

20.

Moarii M, Boeva V, Vert J, Reyal F . Changes in correlation between promoter methylation and gene expression in cancer. BMC Genomics. 2015; 16:873. PMC: 4625954. DOI: 10.1186/s12864-015-1994-2. View